A Randomized, Controlled Study of a Simple, Once-Daily Regimen of Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated, Multidrug-Resistant Falciparum Malaria | Zendy

Elizabeth A. Ashley | Zendy; Rose McGready | Zendy; Robert Hutagalung | Zendy; Lucy Phaiphun | Zendy; Thra Slight | Zendy; Stéphane Proux | Zendy; K. L. Thwai | Zendy; M. Barends | Zendy; S Looareesuwan | Zendy; Nicholas J. White | Zendy; François Nosten | Zendy

Open Access

A Randomized, Controlled Study of a Simple, Once-Daily Regimen of Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated, Multidrug-Resistant Falciparum Malaria

Author(s) -

Elizabeth A. Ashley,

Rose McGready,

Robert Hutagalung,

Lucy Phaiphun,

Thra Slight,

Stéphane Proux,

K. L. Thwai,

M. Barends,

S Looareesuwan,

Nicholas J. White,

François Nosten

Publication year - 2005

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/432011

Subject(s) - piperaquine , regimen , malaria , medicine , dihydroartemisinin , artemisinin , pharmacology , plasmodium falciparum , immunology

Dihydroartemisinin-piperaquine (DP) is a fixed-combination antimalarial drug increasingly deployed in Southeast Asia. The current regimen involves 4 doses given over 3 days. Simplification of the dose regimen should facilitate treatment adherence and thereby increase effectiveness.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research